Thrombolytic therapy: Current clinical practice

Hematology/Oncology Clinics of North America

Volumn 19, Issue 1, 2005, Pages 147-181

  Baker Jr , William F ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KERN MEDICAL CENTER   (United States)

^c California Clinical Thrombosis Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALFIMERASE; ALTEPLASE; ANISTREPLASE; ARGATROBAN; CLOPIDOGREL; DALTEPARIN; DESULFATOHIRUDIN; DIPYRIDAMOLE; ENOXAPARIN; EPTIFIBATIDE; FIBRINOLYTIC AGENT; HEPARIN; HIRUDIN; HIRULOG; LANOTEPLASE; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MONTEPLASE; PAMITEPLASE; RETEPLASE; SARUPLASE; STAPHYLOKINASE; STREPTOKINASE; TENECTEPLASE; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE;

ACUTE HEART INFARCTION; ALLERGY; ARTERY GRAFT; ARTERY THROMBOSIS; ARTIFICIAL EMBOLISM; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DEEP VEIN THROMBOSIS; DISEASE COURSE; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; EDEMA; FEVER; FIBRINOLYTIC THERAPY; HEADACHE; HEART MUSCLE PERFUSION; HUMAN; HYPERTENSION; HYPOTENSION; INTERMETHOD COMPARISON; LUNG EMBOLISM; MORTALITY; NAUSEA; OCCLUSIVE CEREBROVASCULAR DISEASE; PARTIAL THROMBOPLASTIN TIME; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN STRUCTURE; RASH; REVIEW; SIDE EFFECT; STENT; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; VOMITING; CARDIOVASCULAR DISEASE; CHEMISTRY; DRUG CONTRAINDICATION; METHODOLOGY; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; FIBRINOLYTIC AGENTS; HUMANS; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 15544362566     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2004.09.008     Document Type: Review

References (224)

1. A Fletcher The maintenance of a sustained thrombolytic state in man: II. Clinical observations on patients with myocardial infarction and other thromboembolic disorders J Clin Invest 38 1959 11 19
2. E.M. Antman ACC/AHA guidelines for the management of patients with ST-elevation acute myocardial infarction: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction) J Am Coll Cardiol 44 2004 671 719
3. H.P. Adams Guidelines for the early management of patients with ischemic stroke: a scientific statement from the stroke council of the American Stroke Association Stroke 34 2003 1056 1083
4. G.W. Albers Antithrombotic and thrombolytic therapy for ischemic stroke Chest 119 Suppl 1 2001 300S 330S
5. E.M. Ohman Intravenous thrombolysis in acute myocardial infarction Chest 119 Suppl 1 2001 253S 277S
6. G. McNicol The fibrinolytic system Postgrad Med J 49 Suppl 1973 10 17
7. R. Bick Physiology of hemostasis R. Bick Disorders of hemostasis and thrombosis: clinical and laboratory practice 1992 ASCP Press Chicago 1 27
8. R. Bick Physiology of hemostasis and thrombosis R.W. Weinberg B.P. Wilke J. Geffner Disorders of hemostasis and thrombosis: principles of clinical practice 1985 Thieme New York 1 30
9. N. Aoki, M. Moroi, and M. Matsuda The behavior of alpha-2-plasmin inhibitor in fibrinolytic states J Clin Invest 60 1977 361
10. F. Van de Werf, C.P. Cannon, and A. Luyten Safety assessment of a single bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial Am Heart J 137 1999 786 791
11. Assessment of the Safety and Efficacy of a new Thrombolytic Regimen Investigators Single bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomized trial Lancet 354 1999 716
12. C.P. Cannon, C.M. Gibson, and C.H. McCabe TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction. Results of the TIMI 10B trial Circulation 98 1998 2805 2814
13. M.K. Razavi, D.S. Lee, and L.V. Hofmann Catheter-directed thrombolytic therapy for limb ischemia: current status and controversies J Vasc Interv Radiol 15 1 Pt 1 2004 13 23
14. S.R. Deitcher, and M.R. Jaff Pharmacologic and clinical characteristics of thrombolytic agents Rev Cardiovasc Med 3 Suppl 2 2002 S25 S33
15. M.A. Brouwer, N. Clappers, and F.W. Verheugt Adjunctive treatment in patients treated with thrombolytic therapy Heart 90 5 2004 581 588
16. H.M. Hoffmeister Thrombolytic therapy in acute myocardial infarction: comparison of procoagulant effects of streptokinase and alteplase regimens with focus on kallikrein system and plasmin Circulation 98 1998 2527 2533
17. H. Rapold Promotion of thrombin activity by thrombolytic therapy without simultaneous anticoagulation Lancet 1 1990 481 482
18. P. Eisenberg, L.A. Sherman, and A.D. Jaffe Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite fibinolysis J Am Coll Cardiol 10 1987 527 529
19. G.S. Ewald, and P. Eisenberg Plasmin-mediated activation of the contact system in response to pharmacological thrombolysis Circulation 91 1995 28 36
20. P. Eisenberg Factors responsible for the differential procoagulant effects of diverse plasminogen activators in plasma Fibrinolysis 5 1991 217 224
21. P.A. Merlini Activation of the contact system and inflammation after thrombolytic therapy in patients with acute myocardial infarction Am J Cardiol 93 7 2004 822 825
22. M. Davies, A. Thomas, and P. Knapman Intra-myocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death Circulation 73 1986 418 427
23. F.A. Nicolini Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis Circulation 89 1994 1802 1809
24. S. Roux Effects of heparin, aspirin, and synthetic glycoprotein IIb/IIIa receptor antagonist on coronary reperfusion and reocclusion after thrombolysis with tissue-type plasminogen activator in the dog J Pharmacol Exp Ther 264 1993 501 508
25. E.M. Ohman Combined accelerated tissue-plasminogen activator and glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction: results of a randomized, placebo-controlled dose-ranging trial Circulation 95 1997 846 854
26. D.J. Moliterno More complete and stable reperfusion with platelet IIb/IIIa antagonism plus thrombolysis for AMI: the PARADIGM trial [abstract] Circulation 94 Suppl I 1996 I553
27. W. Rote Prevention of rethrombosis after coronary thrombolysis in chronic canine model: adjunctive therapy with monoclonal antibody 7E3 F(ab′) 2 fragment J Cardiovasc Pharmacol 23 1994 194 202
28. S. Cronberg Effect of fibrinolysis on adhesion and aggregation of human platelets Thromb Diathesis Haemorrhage 19 1968 474 482
29. W. Terres Effects of streptokinase, urokinase, and recombinant tissue plasminogen activator on platelet aggregability and stability of platelet aggregates Cardiovasc Res 24 6 1990 471 477
30. D. Fitzgerald Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction Circulation 77 1988 142 150
31. T.K. Nordt Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction Thromb Haemost 80 1998 881 886
32. P.A. Gurbel Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment J Am Coll Cardiol 31 1997 1466 1473
33. S. Coulter High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (Thrombolysis in Myocardial Infarction) 14 Circulation 101 2000 2690 2695
34. J. Herrick Clinical features of sudden obstruction of the coronary arteries JAMA 59 1912 2015 2020
35. M. DeWood Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction N Engl J Med 303 1980 897 902
36. E.C. Keeley, and C.L. Grines Primary coronary intervention for acute myocardial infarction JAMA 291 6 2004 736 739
37. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes. (GUSTO IIb) Angioplasty Substudy Investigators A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction N Engl J Med 336 1997 1621 1628
38. C.M. Gibson Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the thrombolysis in myocardial infarction trials J Am Coll Cardiol 42 2003 7 16
39. E.C. Keeley, J.A. Boura, and C.L. Grines Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction Lancet 361 2003 13 20
40. S. McLean Improving door-to-drug time and ST segment resolution in AMI by moving thrombolysis administration to the emergency department Accid Emerg Nurs 12 1 2004 2 9
41. The GUSTO Investigators An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction N Engl J Med 329 1993 673
42. J.H. Chesebro Thrombolysis in Acute Myocardial Infarction (TIMI) trial, phase 1: a comparison between intravenous plasminogen activator and intravenous streptokinase Circulation 76 1987 142 154
43. M. Verstraete Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction Lancet 1 1985 842 847
44. M. Verstraete Double blind randomized trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction Lancet 2 1985 956 969
45. F.H. Sheehan The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streprokinase from the thrombolysis in myocardial infarction (TIMI phase I) trial Circulation 75 1987 817 829
46. PRIMI Trial Study Group Randomized double-blind trial of recombinant prourokinase against streptokinase in acute myocardial infarction Lancet 1 1989 863
47. Gruppo Italiano per lo Studio della Straptochinasi nell'Infarto Miocardico (GISSI)-1 Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction Lancet 1 1986 397 402
48. Second International Study of Infarct Survival (ISIS-2) Collaborative Group Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction J Am Coll Cardiol 12 6 Suppl A 1988 3A 13A
49. AIMS Trial Study Group Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of placebo-controlled clinical trial Lancet 1 1988 545
50. R. Wilcox Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavia study of early thrombolysis (ASSET) Lancet 2 8610 1988 525 530
51. L.J. Morrison Mortality and prehospital thrombolysis for acute myocardial infarction: a meta-analysis JAMA 283 20 2000 2686 2692
52. W. Lederer Long-term survival and neurological outcome of patients who received recombinant tissue plasminogen activator during out-of-hospital cardiac arrest Resuscitation 61 2 2004 123 129
53. A. Smallwood Nurse-initiated thrombolysis: a systematic review of the literature Nurs Crit Care 9 1 2004 4 12
54. S.L. Grace Presentation, delay, and contraindication to thrombolytic treatment in females and males with myocardial infarction Womens Health Issues 13 6 2003 214 221
55. P.J. Zed Fibrinolytic administration for acute myocardial infarction in a tertiary ED: factors associated with an increased door-to-needle time Am J Emerg Med 22 3 2004 192 196
56. P.G. Steg Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial Circulation 108 23 2003 2851 2856
57. L. Carnendran, and J.S. Steinberg Does an open infarct-related artery after myocardial infarction improve electrical stability? Prog Cardiovasc Dis 42 6 2000 439 454
58. T. Ryan Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction) J Am Coll Cardiol 34 1999 890 911
59. B.R. Brodie Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty J Am Coll Cardiol 32 1998 1312 1319
60. B.R. Brodie Importance of tome to reperfusion on outcomes with primary coronary angioplasty for acute myocardial infarction Am J Cardiol 88 2001 1085 1090
61. M. Dalby Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction Circulation 108 2003 1809 1814
62. W.W. O'Neill A prospective, placebo-controlled, randomized trial of intravenous streptokinase and angioplasty versus lone angioplasty therapy of acute myocardial infarction Circulation 86 1992 1710 1717
63. P. Widimsky Multicenter randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory Eur Heart J 21 2000 823 831
64. F. Vermeer Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities Heart 82 1999 426 431
65. A.M. Ross A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction J Am Coll Cardiol 34 1999 1954 1962
66. M. Cohen, H. Arjomand, and C.V. Pollack Jr The evolution of thrombolytic therapy and adjunctive antithrombotic regimens in acute ST-segment elevation myocardial infarction Am J Emerg Med 22 1 2004 14 23
67. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology Management of acute myocardial infarction in patients presenting with ST-segment elevation Eur Heart J 24 2003 28 66
68. J.M. Juliard Relation of mortality of primary angioplasty during acute myocardial infarction to door-to-Thrombolysis in Myocardial Infarction (TIMI) time Am J Cardiol 91 2003 1401 1405
69. D.O. Williams Treatment delayed is treatment denied Circulation 109 2004 1806 1808
70. C. Fieschi Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours J Neurol Sci 91 3 1989 311 321
71. G.J. del Zoppo Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke Ann Neurol 32 1 1992 78 86
72. B.K. Siesjo Pathophysiology and treatment of focal cerebral ischemia. Part II: mechanisms of damage and treatment J Neurosurg 77 3 1992 337 354
73. S.R. Levine, and T.G. Brott Thrombolytic therapy in cerebrovascular disorders Prog Cardiovasc Dis 34 4 1992 235 262
74. T. Brott, J. Broderick, and R. Kothari Thrombolytic therapy for stroke Curr Opin Neurol 7 1 1994 25 35
75. J.M. Wardlaw, and C.P. Warlow Thrombolysis in acute ischemic stroke: does it work? Stroke 23 12 1992 1826 1839
76. The National Institute of Neurological Disorders and Stroke rtPA Study Group Tissue plasminogen activator for acute ischemic stroke N Engl J Med 333 1995 1581
77. W. Hacke, M. Kaste, and C. Fieschi Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemisperic stroke: the European Cooperative Stroke Study JAMA 274 1995 1017
78. W. Hacke Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators Lancet 352 9136 1998 1245 1251
79. W.M. Clark Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke JAMA 282 21 1999 2019 2026
80. W.M. Clark The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thrombolytic therapy in acute ischemic stroke study investigators Stroke 31 4 2000 811 816
81. Multicenter Acute Stroke Trial-Italy (MAST-I) Group Randomized controlled trial of streptokinase, aspirin and combination of both in treatment of acute ischemic stroke Lancet 346 1995 1509
82. The Australian Streptokinase (ASK) Trial Study Group Streptokinase for acute ischemic stroke with relationship to time of admission JAMA 276 1996 961
83. The Multicenter Stroke Trial-Europe Study Group Thrombolytic therapy with streptokinase in acute ischemic stroke N Engl J Med 335 1996 145
84. G. del Zoppo, R.T. Higashida, and R. Furlan PROACT: a phase II randomized trial of recombinant prourokinase by direct delivery in acute middle cerebral artery stroke Stroke 29 1998 4
85. A. Furlan, R. Higashida, and L. Wechsler A randomized trial of intra-arterial prourokinase for acute ishemic stroke due to middle cerebral artery occlusion JAMA 282 1999 2003
86. A. Furlan Intra-arterial thrombolysis for acute stroke Cleve Clin J Med 71 Suppl 1 2004 S31 S38
87. M. Arnold Clinical and radiological predictors of recanalisation and outcome of 40 patients with acute basilar artery occlusion treated with intra-arterial thrombolysis J Neurol Neurosurg Psychiatry 75 6 2004 857 862
88. C.A. Lewandowski Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy iof acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial Stroke 30 1999 2598 2605
89. T.S. Tomsick Combined IV-IA rtPA treatment in major ischemic stroke [abstract] Stroke 33 2002 359
90. V. Keris Combined intraarterial/intravenous thrombolysis fro acute ischemic stroke Am J Neuroradiol 22 2001 352 358
91. D.H. Lee Local intraarterial urokinase thrombolysis of acute ischemic stroke with or without intravenous abciximab: a pilot study J Vasc Interv Radiol 13 2002 769 774
92. P.P. Ng Intraarterial thrombolysis trials in acute ischemic stroke J Vasc Interv Radiol 15 1 Pt 2 2004 S77 S85
93. E.C. Bourekas Intraarterial thrombolytic therapy within 3 hours of the onset of stroke Neurosurgery 54 1 2004 39 44 [discussion: 44-6]
94. J.M. Wardlaw, C.P. Warlow, and C. Counsell Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke Lancet 350 9078 1997 607 614
95. W. Hacke Thrombolysis in acute ischemic stroke: controlled trials and clinical experience Neurology 53 7 Suppl 4 1999 S3 S14
96. G.D. Graham Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data Stroke 34 12 2003 2847 2850
97. P.D. Schellinger, M. Kaste, and W. Hacke An update on thrombolytic therapy for acute stroke Curr Opin Neurol 17 1 2004 69 77
98. J.A. Chalela Early magnetic resonance imaging findings in patients receiving tissue plasminogen activator predict outcome: insights into the pathophysiology of acute stroke in the thrombolysis era Ann Neurol 55 1 2004 105 112
99. S. Straub Systemic thrombolysis with recombinant tissue plasminogen activator and tirofiban in acute middle cerebral artery occlusion Stroke 35 3 2004 705 709
100. M.J. Alberts Recommendations for the establishment of primary stroke centers: Brain Attack Coalition JAMA 283 2001 3102 3109
101. J.W. Norris Canadian guidelines for intravenous thrombolytic treatment in acute stroke: a consensus statement of the Canadian Stroke Consortium Can J Neurol Sci 25 1998 257 259
102. I. Aboderin, and G. Venables Stroke management in Europe: Pan European Consensus Meeting on Stroke Management J Intern Med 240 1996 173 180
103. T. Moulin Early CT signs in acute middle cerebral artery infarction: predictive value for subsequent infarct locations and outcome Neurology 47 1996 366 375
104. R. von Kummer Detectability of cerebral hemisphere ischaemic infarcts by CT within 6 h of stroke Neuroradiology 38 1996 31 33
105. R. von Kummer Acute stroke: usefulness of early CT findings before thrombolytic therapy Radiology 205 1997 327 333
106. J. Kwan, P. Hand, and P. Sandercock A systematic review of barriers to delivery of thrombolysis for acute stroke Age Ageing 33 2 2004 116 121
107. W. Bell, E. Black, and D. DeMets Urokinase pulmonary embolism trial JAMA 214 1970 2163
108. W. Bell Urokinase-streptokinase embolism trial, phase 2 results JAMA 229 1974 1606 1613
109. V.J. Marder The use of thrombolytic agents: choice of patient, drug administration, laboratory monitoring Ann Intern Med 90 5 1979 802 808
110. S.Z. Goldhaber Randomized controlled trial of recombinant tissue plasminogen activator versus urokinase in th treatment of acute pulmonary embolism Lancet 2 1988 293
111. S.Z. Goldhaber Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis Am J Med 88 3 1990 235 240
112. E. Immelman, and P. Jeffrey The post-phlebitic syndrome. Pathophysiology prevention and management Clin Chest Med 5 1984 537
113. H. Arnesen, A. Hoiseth, and B. Ly Streptokinase of heparin in the treatment of deep vein thrombosis. Follow-up results of a prospective study Acta Med Scand 211 1-2 1982 65 68
114. M.S. Elliot A comparative randomized trial of heparin versus streptokinase in the treatment of acute proximal venous thrombosis: an interim report of a prospective trial Br J Surg 66 12 1979 838 843
115. R. Watz, and G.F. Savidge Rapid thrombolysis and preservation of valvular venous function in high deep vein thrombosis. A comparative study between streptokinase and heparin therapy Acta Med Scand 205 4 1979 293 298
116. H.H. Common Deep vein thrombosis treated with streptokinase or heparin. Follow-up of a randomized study Angiology 27 11 1976 645 654
117. L. Johansson Comparison of streptokinase with heparin: late results in the treatment of deep venous thrombosis Acta Med Scand 206 1-2 1979 93 98
118. V.V. Kakkar, and D. Lawrence Hemodynamic and clinical assessment after therapy for acute deep vein thrombosis. A prospective study Am J Surg 150 4A 1985 54 63
119. P. Prandoni The long-term clinical course of acute deep venous thrombosis Ann Intern Med 125 1996 1 7
120. F. Navarro, and S. Dean Young patients with iliofemoral deep venous thrombosis should receive thrombolytic therapy Med Clin North Am 87 6 2003 1165 1177
121. A.G. Turpie Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis. Results of a randomized trial Chest 97 Suppl 4 1990 172S 175S
122. T.M. Hyers Antithrombotic therapy for venous thromboembolic disease Chest 119 Suppl 1 2001 176S 193S
123. A.J. Comerota A strategy of aggressive regional therapy for acute iliofemoral venous thrombosis with contemporary venous thrombectomy or catheter-directed thrombolysis J Vasc Surg 20 2 1994 244 254
124. C.P. Semba, and M.D. Dake Iliofemoral deep venous thrombosis: aggressive therapy with catheter-directed thrombolysis Radiology 191 2 1994 487 494
125. R. Verhaeghe, and G. Maleux Endovascular local thrombolytic therapy of ileofemoral and inferior caval vein thrombosis Semin Vasc Med 1 1 2001 123 128
126. H. Bjarnason Iliofemoral deep venous thrombosis: safety and efficacy outcome during 5 years of catheter-directed thrombolytic therapy J Vasc Interv Radiol 8 3 1997 405 418
127. M.W. Mewissen Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry Radiology 211 1 1999 39 49
128. V.J. Marder, and S. Sherry Thrombolytic therapy: current status N Engl J Med 318 23 1988 1512 1520
129. S.Z. Goldhaber Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion Lancet 341 8844 1993 507 511
130. S.Z. Goldhaber, G. Agnelli, and M.N. Levine Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group Chest 106 3 1994 718 724
131. N. Meneveau Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up J Am Coll Cardiol 31 5 1998 1057 1063
132. S. Konstantinides Comparison of alteplase versus heparin for resolution of major pulmonary embolism Am J Cardiol 82 8 1998 966 970
133. G.V. Sharma, V.A. Burleson, and A.A. Sasahara Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism N Engl J Med 303 15 1980 842 845
134. U. Tebbe Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism Am Heart J 138 1 Pt 1 1999 39 44
135. S.Z. Goldhaber Management of deep vein thrombosis and pulmonary embolism Clin Cornerstone 2 4 2000 47 55
136. J.M. Murphy Percutaneous catheter and guidewire fragmentation with local administration of recombinant tissue plasminogen activator as a treatment for massive pulmonary embolism Eur Radiol 9 1999 959 964
137. M. Verstraete Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism Circulation 77 2 1988 353 360
138. J.E. Dalen, J.S. Alpert, and J. Hirsch Thrombolytic therapy for pulmonary embolism: is it effective? Is it safe? When is it indicated? Arch Intern Med 157 22 1997 2550 2556
139. M.V. McConnell Regional right ventricular dysfunction detected by echocardiography in acute pulmonary embolism Am J Cardiol 78 4 1996 469 473
140. S.Z. Goldhaber, and H. Bounameaux Thrombolytic therapy in pulmonary embolism Semin Vasc Med 1 2 2001 213 220
141. S.Z. Goldhaber Thrombolysis for pulmonary embolism N Engl J Med 347 2002 1131 1132
142. J. Hirsh, and J. Hoak Management of deep vein thrombosis and pulmonary embolism: a statement for healthcare professionals Circulation 93 1996 2212 2245
143. S.A. Nasraway, N. Kabani, and K.R. Lawrence Thrombolytic therapy for pulmonary embolism: reversal of shock in the early postoperative period Pharmacotherapy 14 5 1994 616 619
144. P. Severi Urokinase thrombolytic therapy of pulmonary embolism in neurosurgically treated patients Surg Neurol 42 6 1994 469 470
145. P.K. Mazeka, and C.M. Oakley Massive pulmonary embolism in pregnancy treated with streptokinase and percutaneous catheter fragmentation Eur Heart J 15 9 1994 1281 1283
146. I. Kurkciyan Pulmonary embolism as a cause of cardiac arrest: presentation and outcome Arch Intern Med 160 10 2000 1529 1535
147. B.W. Bottinger High-dose bolus injection of urokinase. Use during cardiopulmonary resuscitation for massive pulmonary embolism Chest 106 4 1994 1281 1283
148. T. Schmitz-Rode Massive pulmonary embolism: percutaneous emergency treatment by pigtail rotation catheter J Am Coll Cardiol 36 2 2000 375 380
149. W. Lapanum Major pulmonary embolism and shock. Persistent hypotension after thrombolysis treated with improvised mechanical fragmentation of thrombus Med J Aust 179 9 2003 495 496
150. S. Konstantinides Thrombolysis in submassive pulmonary embolism? Yes J Thromb Haemost 1 2003 1127 1129
151. J.E. Dalen Thrombolysis in submassive pulmonary embolism? No J Thromb Haemost 1 2003 1130 1132
152. W. Kasper Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry J Am Coll Cardiol 30 1997 1165 1171
153. S. Konstantinides Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism Circulation 96 1997 882 888
154. S. Konstantinides Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism N Engl J Med 347 2002 1143 1150
155. S. Konstantinides Should thrombolytic therapy be used in patients with pulmonary embolism? Am J Cardiovasc Drugs 4 2 2004 69 74
156. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) V Investigators A comparison of heparin plus full, bolus dose reteplase with half-dose reteplase plus abciximab plus heparin in patients with acute myocardial infarction Lancet 357 2001 1905
157. J.J. O'Meara A decision analysis of streptokinase plus heparin as compared with heparin alone for deep-vein thrombosis N Engl J Med 330 1994 1864 1869
158. M. Verstraete, J. Vermylen, and M.B. Donati The effect of streptokinase infusion on chronic arterial occlusions and stenoses Ann Intern Med 74 3 1971 377 382
159. L.T. Cotton, P.T. Flute, and M.J. Tsapogas Popliteal artery thrombosis treated with streptokinase Lancet 2 1962 1081 1083
160. A. Amery Outcome of recent thromboembolic occlusions of limb arteries treated with streptokinase BMJ 4 736 1970 639 644
161. G.A. Sicard Thrombolytic therapy for acute arterial occlusion J Vasc Surg 2 1 1985 65 78
162. J.W. Hallett Jr Statistical determinants of success and complications of thrombolytic therapy for arterial occlusion of lower extremity Surg Gynecol Obstet 161 5 1985 431 437
163. L.S. Chaise Selective intra-arterial streptokinase therapy in the immediate postoperative period JAMA 247 17 1982 2397 2400
164. H. Hess Local low-dose thrombolytic therapy of peripheral arterial occlusions N Engl J Med 307 26 1982 1627 1630
165. G.A. Berni Streptokinase treatment of acute arterial occlusion Ann Surg 198 2 1983 185 191
166. K. Ouriel, F. Veith, and A.A. Sasahara Investigators for the Thrombolysis or Peripheral Artery Surgery (TOPAS). A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs N Engl J Med 338 1998 1105
167. K. Ouriel A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia J Vasc Surg 19 6 1994 1021 1030
168. Working Party on Thrombolysis in the Management of Limb Ischemia Thrombolysis in the management of lower limb peripheral arterial occlusion: a consensus document Am J Cardiol 81 1998 207 218
169. T.O. McNamara, and J.R. Fischer Thrombolysis of peripheral arterial and graft occlusions: improved results using high-dose urokinase AJR Am J Roentgenol 144 4 1985 769 775
170. K. Ouriel, F.J. Veith, and A.A. Sasahara Thrombolysis or peripheral arterial surgery: phase I results. TOPAS Investigators J Vasc Surg 23 1996 64 73
171. A.S. Ward, S.K. Andaz, and S. Bygrave Peripheral thrombolysis with tissue plasminogen activator: results of two treatment regimens Arch Surg 129 1994 861 865
172. B.D. Braithwaite, T.M. Buckenham, R.B. Galland on behalf of the Thrombolysis Study Group Prospective randomized trial of high-dose versus low-dose tissue plasminogen activator infusion in the management of acute limb ischemia Br J Surg 84 1997 646 650
173. K. Ouriel Reteplase in the treatment of peripheral arterial and venous occlusions: a pilot study J Vasc Interv Radiol 11 2000 849 854
174. F. Castaneda Declining-dose study of reteplase treatment for lower extremity arterial occlusions J Vasc Interv Radiol 13 2002 1093 1098
175. F. Mahler, E. Schneider, and H. Hess Recombinant tissue plasminogen activator versus urokinase for local thrombolysis of femoropopliteal occlusions: a prospective, randomized multicenter trial J Endovasc Ther 8 2001 638 647
176. The STILE Investigators Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. The STILE Trial Ann Surg 220 1994 251
177. M.M. Davidian Initial results of reteplase in the treatment of acute lower extremity arterial occlusions J Vasc Interv Radiol 11 2000 289 294
178. F. Castaneda Catheter-directed thrombolysis in deep venous thrombosis with the use of reteplase: immediate results and complications from a pilot study J Vasc Interv Radiol 13 2002 577 580
179. M.K. Razavi Initial clinical results of tenecteplase (TNK) in catheter-directed thrombolytic therapy J Endovasc Ther 9 2002 593 598
180. D.J. Burkart Thrombolysis of occluded peripheral arteries and veins with tenecteplase: a pilot study J Vasc Interv Radiol 13 2002 1099 1102
181. N. Patel SCVIR reporting standards for the treatment of acute limb ischemia with the use of transluminal removal of arterial thrombus J Vasc Interv Radiol 12 2001 559 570
182. S.J. Weatherby Good outcome in early pregnancy following direct thrombolysis for cerebral venous sinus thrombosis J Neurol 250 11 2003 1372 1373
183. K.R. Murry, D.H. Rhoney, and W.M. Coplin Urokinase in the treatment of intraventricular hemorrhage Ann Pharmacother 32 2 1998 256 258
184. S. Amin-Hanjani, C.S. Ogilvy, and F.G. Barker Jr Does intracisternal thrombolysis prevent vasospasm after aneurysmal subarachnoid hemorrhage? A meta-analysis Neurosurgery 54 2 2004 326 334 [discussion: 334-5]
185. W.A. Lee Surgical intervention is not required for all patients with subclavian vein thrombosis J Vasc Surg 32 1 2000 57 67
186. H.C. Urschel Jr, and M.A. Razzuk Paget-Schroetter syndrome: what is the best management? Ann Thorac Surg 69 6 2000 1663 1668 [discussion: 1668-9]
187. F.W. Leebeek Budd-Chiari syndrome, portal vein and mesenteric vein thrombosis in a patient homozygous for factor V Leiden mutation treated by TIPS and thrombolysis Br J Haematol 102 4 1998 929 931
188. T. Bhattacharjya Percutaneous portal vein thrombolysis and endovascular stent for management of post transplant portal venous conduit thrombosis Transplantation 69 10 2000 2195 2198
189. E.A. Henao, W.T. Bohannon, and M.B. Silva Jr Treatment of portal venous thrombosis with selective superior mesenteric artery infusion of recombinant tissue plasminogen activator J Vasc Surg 38 6 2003 1411 1415
190. H. Silber The St. Jude valve. Thrombolysis as the first line of therapy for cardiac valve thrombosis Circulation 87 1993 30 37
191. Y. Shapira Thrombolysis is an effective and safe therapy in stuck bileaflet mitral valves in the absence of high-risk thrombi J Am Coll Cardiol 35 7 2000 1874 1880
192. R. Roudaut Fibrinolysis of mechanical prosthetic valve thrombosis: a single center study of 127 cases J Am Coll Cardiol 41 2003 653 658
193. N. Durrleman Prosthetic valve thrombosis: twenty-year experience at the Montreal Heart Institute J Thorac Cardiovasc Surg 127 5 2004 1388 1392
194. A. Agazzi Local thrombolytic therapy in cancer patients with central venous catheter occlusion in urgent need of antiblastic treatment: a single institution experience J Thromb Thrombolysis 15 2 2003 109 111
195. V.J. Marder Thrombolytic therapy: foundations and results R. Colman J. Hirsh V.J. Marder Hemostasis and thrombosis: basic principles and clinical practice 4th edition 2001 Lippincott Philadelphia 1475
196. J. Gore, C. Granger, and M. Simoons Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-1 trial. Global Use of Strategies to Open Occluded Coronary Artery Circulation 92 1995 2811
197. D.E. Kandzari Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial) Am J Cardiol 93 4 2004 458 461
198. J. Leopold, J. Keaney, and J. Loscalzo Pharmacology of thrombolytic agents J. Loscalzo A. Schafer Thrombosis and hemorrhage 1998 Williams and Wilkins Baltimore 1215 1258
199. Investigators of the International Joint Efficacy Comparison of Thrombolytics (INJECT) Randomized, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence Lancet 346 1995 329
200. J.H. Gurwitz Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2 Ann Intern Med 129 8 1998 597 604
201. C.P. Cannon Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial J Am Coll Cardiol 24 1994 1604 1610
202. R. Smalling More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction Circulation 91 1995 2725 2732
203. C.P. Cannon TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombloysis in Myocardial infarction (TIMI) 10. A dose-ranging trial Circulation 95 1997 351
204. The TIMI Study Group Thrombolysis in Myocardial Infarction (TIMI) trial phase I findings N Engl J Med 312 1985 932
205. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico GISSI-2: a factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction Lancet 336 1990 65
206. Third International Study of Infarct Survival (ISIS-3) Collaborative Group ISIS3: a randomized comparison of streptokinase versus tissue plasminogen activator versus anistreplase and of aspirin plus heparin versus aspirin alone among 14,299 cases of suspected acute myocardial infarction Lancet 339 1992 753
207. The GUSTO Angiographic Investigators The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction N Engl J Med 329 1993 1615
208. C. Bode Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction Circulation 94 1995 891
209. The Global Use of Strategies to Open Occluded Coronary Arteries. (GUSTO-III) Investigators A comparison of reteplase with alteplase for acute myocardial infarction N Engl J Med 337 1997 1118
210. N. Kleiman Profound inhibition of platelet aggregation with monoclonal antibody 7E3 fab following thrombolytic therapy: results of the TAMI 8 pilot study J Am Coll Cardiol 22 1993 381 389
211. Strategies for Patency Enhancement in the Emergency Department (SPEED) Trial Group Trial of abciximab with and without low-dose reteplase for acute myocardial infarction: Strategies for Patency Enhancement in the Emergency Department (SPEED) Circulation 101 2000 2788
212. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen Investigators Efficacy and safety of tenecteplase in combination with enoxaparin, abcixmab, or unfractionated heparin: the ASSENT-3 randomized trial in acute myocardial infarction Lancet 358 2001 605
213. S. Brener Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction. The Integrilin and Low-Dose Thrombolysis in Acute Myocardial Infraction (INTRO-AMI) trial J Am Coll Cardiol 39 2003 377 386
214. R.P. Giugliano Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction. Results of the Integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) phase II angiographic trial J Am Coll Cardiol 41 2003 1251 1260
215. E.M. Antman Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators Circulation 99 21 1999 2720 2732
216. The InTIME-II Investigators Intravenous NPA for the treatment of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute mycardial infarction Eur Heart J 21 2000 2005
217. L. Wallentin Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study Eur Heart J 24 2003 897 908
218. M.L. Simoons Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK study Eur Heart J 23 2002 1282 1290
219. A.M. Ross Randomized comparison of enoxaparin, a low- molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II) Circulation 104 2001 648 652
220. L. Lee Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial Am J Cardiol 75 1995 7 13
221. E.M. Antman Hirudin in acute myocardial infarction: Thrombolysis and Thrombin in Myocardial Infarction (TIMI) 9b trial Circulation 94 1996 911 921
222. K. Neuhaus Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HITT-III) study: a study of the Arbeirsgemeinschaft Leitender Kardiologischer Krankenhausarzte (ALKK) Circulation 90 1994 1638 1642
223. The Hirulog and Early Reperfusion or Occlusion (HERO) 2 Trial Investigators Thrombin-specific anticoagulation with bivalrudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: The HERO-2 randomized trial Lancet 358 2001 1855
224. X.Q. Zhao Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms.) PRISM-PLUS Investigators Circulation 100 15 1999 1609 1615